or
Bookmark and Share
Adipose-derived stem cells and lattices
   
Document Number
US Patent 6777231
Issued Date
August 17, 2004
Link
Inventors
Katz; Adam J. (Charlottesville, VA)
Benhaim; Prosper (Los Angeles, CA)
Zhu; Min (Los Angeles, CA)
Map
Abstract
The present invention provides adipose-derived stem cells and lattices. In one aspect, the present invention provides a lipo-derived stem cell substantially free of adipocytes and red blood cells and clonal populations of connective tissue stem cells. The cells can be employed, alone or within biologically-compatible compositions, to generate differentiated tissues and structures, both in vivo and in vitro. Additionally, the cells can be expanded and cultured to produce hormones and to provide conditioned culture media for supporting the growth and expansion of other cell populations. In another aspect, the present invention provides a lipo-derived lattice substantially devoid of cells, which includes extracellular matrix material from adipose tissue. The lattice can be used as a substrate to facilitate the growth and differentiation of cells, whether in vivo or in vitro, into anlagen or even mature tissues or structures.
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
10
Comments:
no comments yet
Published
August 17, 2004
Application Number
09/936,665
Filed
September 10, 2001
US Classification
435/325   435/366
Int'l Classification
C12N   5/00   (20060101)   C12N   5/06   (20060101)   A61K   35/12   (20060101)   A61K   48/00   (20060101)  
Examiner
Assistant Examiner
Attorney/Law Firm
Parent Case
This application is a:: 371 of Application One:: PCT/US00/06232 Filing Date:: Mar. 10, 2000 Which is a::NON PROV. OF PROVISIONAL Application Two:: 60/123,711 Filing Date:: Mar. 10, 1999 And which is a:: NON PROV. OF PROVISIONAL Application Three:: 60/162,462 Filing Date:: Oct. 29, 1999
USPTO Field of Search
435/325   435/366  
Related Patents
7531355 - Methods and compositions for smooth muscle reconstruction - Owned by The Regents of the University of California (Oakland, CA)

This invention also provides a purified or isolated population of ADSCs that can differentiate into a cell of the leiomyogenic lineage, e.g., smooth muscle or skeletal muscle. In yet another aspect, the population additionally can be differentiated into a lineage selected from the group consisting of osteogenic, adipogenic, chondrogenic, myogenic and neuronal. This invention further provides a composition comprising a substantially homogeneous expanded population of smooth muscle cells. This invention provides a composition comprising a substantially homogeneous expanded population of skeletal muscle cells. Also provided herein is an isolated composition comprising a purified adipose-derived stem cell (ADSC) or progeny of said ADSC and an effective amount of laminin or heparin, effective to induce leiomyogenic differentiation. Diagnositic and therapeutic uses for these compositions are provided herein.

7501115 - Systems and methods for treating patients with processed lipoaspirate cells - Owned by Cytori Therapeutics, Inc. (San Diego, CA)

Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.

7473420 - Systems and methods for treating patients with processed lipoaspirate cells - Owned by Cytori Therapeutics, Inc. (San Diego, CA)

Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.

7470537 - Adipose-derived stem cells and lattices

The present invention provides adipose-derived stem cells (ADSCs), adipose-derived stem cell-enriched fractions (ADSC-EF) and adipose-derived lattices, alone and combined with the ADSCs of the invention. In one aspect, the present invention provides an ADSC substantially free of adipocytes and red blood cells and clonal populations of connective tissue stem cells. The ADSCs can be employed, alone or within biologically-compatible compositions, to generate differentiated tissues and structures, both in vivo and in vitro. Additionally, the ADSCs can be expanded and cultured to produce molecules such as hormones, and to provide conditioned culture media for supporting the growth and expansion of other cell populations. In another aspect, the present invention provides an adipose-derived lattice substantially devoid of cells, which includes extracellular matrix material from adipose tissue. The lattice can be used as a substrate to facilitate the growth and differentiation of cells, whether in vivo or in vitro, into anlagen or even mature tissues or structures.

7429488 - Method for processing lipoaspirate cells - Owned by Cytori Therapeutics, Inc. (San Diego, CA)

Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.

Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us